FDA PreCheck Pilot Program: How Early Facility Engagement Accelerates Domestic Pharma Manufacturing

The pharmaceutical industry has grappled with an uncomfortable paradox for more than a decade. While the United States remains the world’s largest market for prescription drugs, a substantial majority of the active pharmaceutical ingredients and finished dosage forms consumed domestically are manufactured overseas. Supply chain disruptions during the pandemic years exposed the fragility of this arrangement in ways that regulatory agencies, lawmakers, and industry executives could no longer ignore.

The FDA’s Manufacturing PreCheck Pilot Program represents one of the most meaningful structural changes to the agency’s relationship with domestic manufacturers in recent memory. Rather than evaluating manufacturing facilities only after a drug application has been submitted, PreCheck creates a formal pathway for early engagement between the FDA and companies building or upgrading production capacity within the United States. The goal is straightforward but ambitious: reduce the regulatory friction that has historically made domestic pharmaceutical manufacturing slower and more uncertain than it needs to be.

For IT leaders, quality operations executives, and digital transformation teams within pharma and biotech organizations, this program carries implications that extend well beyond regulatory strategy. PreCheck participation demands a certain caliber of digital infrastructure, data management maturity, and quality system readiness that many organizations will need to build or significantly upgrade. Understanding the program’s mechanics, requirements, and strategic value is essential for any organization considering domestic manufacturing expansion.

What Is the FDA PreCheck Pilot Program

The FDA Manufacturing PreCheck Pilot Program is a voluntary initiative that allows pharmaceutical manufacturers to engage with the agency on facility readiness before submitting a marketing application. Traditionally, the FDA evaluates a manufacturing facility’s compliance with current Good Manufacturing Practice (cGMP) requirements as part of reviewing a New Drug Application (NDA), Abbreviated New Drug Application (ANDA), or Biologics License Application (BLA). This means that any deficiencies discovered during pre-approval inspection can delay or derail an otherwise approvable product.

PreCheck inverts this sequencing. By enabling manufacturers to work with the FDA on facility qualification earlier in the development lifecycle, the program aims to identify and resolve potential compliance issues before they become bottlenecks in the application review process. The initiative focuses specifically on facilities located within the United States, reflecting a broader policy priority around strengthening domestic manufacturing capacity for essential medicines.

The program was announced in early 2026 as part of a series of FDA initiatives aimed at modernizing the agency’s approach to pharmaceutical manufacturing oversight. It operates alongside existing programs like the Emerging Technology Program and the Knowledge-Aided Assessment and Structured Application (KASA) initiative, but addresses a different gap: the structural disconnect between facility investment decisions and regulatory approval timelines.

Why PreCheck Matters for Domestic Manufacturing

The strategic context for PreCheck is inseparable from the ongoing conversation about pharmaceutical supply chain resilience. Data from FDA drug shortage databases consistently shows that a significant percentage of shortages stem from manufacturing quality problems, facility shutdowns, or capacity constraints. When the primary production base for a given API or finished product sits entirely outside the United States, the options for rapid response to these disruptions are limited.

Several converging forces have elevated the urgency of domestic manufacturing capacity:

• Geopolitical risk: Concentration of API production in a small number of countries creates vulnerability to trade disputes, export restrictions, and regional instability
• Drug shortage patterns: Recurring shortages of essential medications have prompted Congressional attention and executive action
• Federal incentive programs: New financial incentives for domestic pharmaceutical manufacturing require corresponding regulatory pathways to be effective
• Quality assurance considerations: Proximity between manufacturing sites and the regulatory agency enables more frequent and thorough oversight

PreCheck addresses a specific barrier that has discouraged domestic facility investment. Building or retrofitting a pharmaceutical manufacturing plant requires capital commitments measured in hundreds of millions of dollars and construction timelines spanning multiple years. Without early clarity on whether the FDA will find the facility acceptable, companies face substantial financial risk. A facility that passes PreCheck assessment carries significantly lower regulatory uncertainty, making the investment case more compelling for boards and investors.

How the PreCheck Process Works

The PreCheck process unfolds in several distinct phases, each designed to build progressively on the information gathered in the previous stage. While the FDA has maintained some flexibility in how the program operates during the pilot phase, the general structure follows a consistent pattern.

Phase 1: Expression of Interest and Initial Screening

Manufacturers begin by submitting an expression of interest to the FDA’s Office of Pharmaceutical Quality (OPQ). This initial submission outlines the facility’s location, planned manufacturing capabilities, product categories under consideration, and the organization’s timeline for operational readiness. The FDA reviews these submissions to determine whether the facility and manufacturer meet the basic eligibility requirements for program participation.

Phase 2: Facility Information Package Submission

Accepted participants prepare and submit a comprehensive facility information package. This documentation goes well beyond a typical site master file. It encompasses detailed descriptions of the facility’s quality management system, manufacturing process capabilities, environmental monitoring programs, equipment qualification status, and personnel training infrastructure. The FDA evaluates this package to develop an initial assessment of the facility’s cGMP readiness.

Phase 3: Collaborative Assessment and Gap Analysis

This is where PreCheck diverges most dramatically from traditional regulatory engagement. The FDA conducts a collaborative review of the facility information, working with the manufacturer to identify gaps or areas requiring remediation. This is not an adversarial inspection but a consultative process aimed at helping the facility achieve compliance before any product-specific application is filed.

Phase 4: On-Site Assessment

Following the document review and gap remediation, the FDA conducts an on-site assessment of the facility. This visit evaluates the physical plant, equipment, processes, and quality systems in operation. Findings from this assessment are shared with the manufacturer along with specific recommendations for any remaining improvements.

Phase 5: PreCheck Determination

Based on the cumulative assessment, the FDA issues a PreCheck determination for the facility. A favorable determination signals that the facility meets baseline cGMP requirements and is positioned to support product-specific applications with reduced pre-approval inspection requirements. This determination is not permanent and does not replace product-specific regulatory review, but it provides a meaningful head start.

Eligibility Criteria and Application Requirements

Not every manufacturer or facility qualifies for the PreCheck pilot. The FDA has established specific criteria that reflect the program’s dual objectives of strengthening domestic capacity and ensuring that participating facilities meet high standards of manufacturing quality.

Geographic requirement: The facility must be located within the United States or its territories. This requirement is non-negotiable and reflects the program’s explicit focus on domestic manufacturing capacity. Contract manufacturing organizations (CMOs) with U.S.-based facilities are eligible, provided they meet other criteria.

Manufacturing scope: The program currently covers facilities producing human drugs, including active pharmaceutical ingredients, finished dosage forms, and biological products. The facility must be engaged in or planning to engage in manufacturing activities that would be subject to FDA pre-approval inspection under existing regulations.

Organizational readiness: Applicants must demonstrate that they have an established quality management system, even if the facility itself is still under construction or commissioning. The FDA expects to see evidence of a functioning quality unit, documented procedures, and a commitment to cGMP compliance that extends beyond paper documentation.

Drug shortage relevance: While not a strict eligibility requirement, the FDA has indicated a preference for facilities that will manufacture products on the drug shortage list or products for which domestic supply chain resilience is particularly important. Manufacturers producing essential medicines, critical care drugs, or products with limited domestic competition may receive priority consideration.

The FDA Implementation Roadmap

The agency published a PreCheck implementation roadmap that outlines how the pilot will evolve over its initial operating period. Understanding this roadmap is important for organizations considering participation, as the program’s scope and procedures will likely expand and become more structured over time.

During the initial pilot phase, the FDA is working with a limited number of facilities to refine the assessment process, develop standardized evaluation criteria, and build internal capacity for conducting PreCheck reviews. The agency has acknowledged that its own workforce and procedures need to adapt to this new model of engagement, and the pilot phase serves as a learning opportunity for both the FDA and participating manufacturers.

Key milestones in the roadmap include the development of standardized facility assessment templates, creation of guidance documents for participants, establishment of metrics for measuring program effectiveness, and eventual publication of a framework for transitioning from pilot to permanent program status. The FDA has also signaled that data gathered during the pilot will inform broader policy decisions about manufacturing oversight modernization.

For organizations planning facility investments with multi-year timelines, the evolving nature of the program is worth monitoring carefully. Early participants will have the advantage of helping shape the program’s standards, but they will also face more uncertainty about specific requirements than later entrants will encounter once the program matures.

Key Benefits for Pharmaceutical Manufacturers

The potential benefits of PreCheck participation extend across multiple dimensions of the pharmaceutical business, from regulatory timelines to financial planning to competitive positioning.

Accelerated Time to Market

The most immediate benefit is the potential reduction in time between application submission and approval. When a facility has already received a favorable PreCheck determination, the pre-approval inspection process for specific products manufactured at that facility can be streamlined. The FDA may determine that a focused inspection rather than a comprehensive one is sufficient, or that certain aspects of the facility assessment do not need to be repeated.

For organizations launching generic drugs under ANDAs, where speed to market directly determines competitive positioning and revenue capture, even a few months of time savings can translate to significant financial impact. For innovator companies with novel therapeutics, faster facility clearance means earlier patient access and extended effective patent life.

Reduced Regulatory Uncertainty

Capital investment decisions in pharmaceutical manufacturing are heavily influenced by regulatory risk. A facility that costs several hundred million dollars to build but cannot pass FDA inspection represents an existential financial threat to mid-size manufacturers and a significant writedown risk for larger companies. PreCheck provides an early signal on facility acceptability, enabling more confident investment decisions and more credible business case presentations to boards and investors.

Enhanced Supply Chain Resilience

Organizations that successfully navigate PreCheck will be positioned to bring domestic manufacturing capacity online more quickly, contributing to supply chain resilience both for their own product portfolios and for the broader pharmaceutical market. This capability has strategic value in an environment where customers, payers, and regulators increasingly value supply chain diversity and domestic sourcing.

Digital Infrastructure Requirements for Participation

This is where the FDA PreCheck pilot program intersects most directly with the responsibilities of IT leaders and digital transformation teams. The level of documentation, data management, and process transparency required for effective PreCheck participation demands robust digital infrastructure that goes beyond basic compliance systems.

Electronic Quality Management Systems

Participants need a mature electronic quality management system (eQMS) that can support the documentation requirements of the PreCheck assessment. This includes electronic document control, training management, deviation and CAPA tracking, change control workflows, and audit management. The system must produce reliable, audit-ready outputs that demonstrate the facility’s quality management maturity.

Data Integrity Infrastructure

The FDA’s increasing focus on data integrity makes this a critical area for PreCheck readiness. Manufacturing systems, laboratory instruments, and quality databases must comply with ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available). This requires investment in audit trail capabilities, electronic signature infrastructure, backup and recovery systems, and access control frameworks.

Manufacturing Execution Systems

Facilities participating in PreCheck should have manufacturing execution systems (MES) or equivalent digital platforms that provide real-time visibility into production processes, batch records, and environmental conditions. The ability to demonstrate process control through digital records significantly strengthens the facility assessment outcome.

Integrated Environmental Monitoring

Environmental monitoring systems for cleanroom classification, temperature mapping, particulate counting, and microbial monitoring need to be digitally integrated and capable of producing trend analyses and exception reports. Manual logbook approaches are increasingly inadequate for the level of scrutiny that PreCheck assessments involve.

Quality Systems Readiness and GMP Considerations

Digital infrastructure is a necessary but not sufficient condition for PreCheck success. The broader quality system must be mature, well-documented, and genuinely operational rather than merely documented. The FDA’s assessment will probe beyond surface-level compliance to evaluate whether the organization’s quality culture supports sustained manufacturing excellence.

Quality Management Maturity Model

Organizations preparing for PreCheck should evaluate their quality systems against the FDA’s Pharmaceutical Quality System (PQS) framework, which draws from ICH Q10. Key elements include management responsibility and commitment, a comprehensive pharmaceutical quality system, process performance and product quality monitoring, and a robust corrective and preventive action program.

The FDA is particularly interested in evidence that the quality system operates proactively rather than reactively. Organizations that can demonstrate trending and predictive analytics based on quality data, systematic use of risk assessment tools, and continuous improvement driven by data analysis will present a more compelling case than those relying on incident-response approaches.

Validation and Qualification Programs

Equipment qualification (IQ/OQ/PQ), process validation, cleaning validation, and computer system validation programs must be current and comprehensive. For new or under-construction facilities, the validation master plan should clearly articulate the approach, timeline, and acceptance criteria for all validation activities. The FDA will evaluate the rigor and completeness of the validation strategy as part of the PreCheck assessment.

Supply Chain Quality Management

The quality system must extend beyond the facility walls to encompass supplier qualification and oversight, especially for critical raw materials, primary packaging components, and contract services. A facility that meets internal cGMP standards but lacks robust supplier management represents a risk that the PreCheck assessment will identify.

Strategic Implications for Industry Leaders

The PreCheck pilot program is not merely a procedural innovation. It represents a shift in how the FDA conceptualizes its relationship with domestic manufacturers, and industry leaders should consider the broader strategic implications of this shift.

Reshoring and Nearshoring Decisions

For companies evaluating whether to build or expand manufacturing capacity in the United States versus continuing to rely on overseas production, PreCheck changes the calculus. The program does not eliminate the cost differential between domestic and offshore manufacturing, but it does reduce one of the significant non-financial costs: regulatory timeline uncertainty. When combined with federal incentive programs and growing customer demand for domestic sourcing, PreCheck may tip the balance for organizations on the fence about reshoring decisions.

M&A and Partnership Considerations

A facility with a favorable PreCheck determination becomes a more valuable asset in merger, acquisition, and partnership scenarios. Contract manufacturing organizations that achieve PreCheck status will have a differentiated offering that can command premium pricing. Companies evaluating manufacturing partnerships should consider PreCheck status as a factor in partner selection.

Investor and Board Communication

The ability to point to a favorable PreCheck determination when presenting manufacturing investment plans to boards and investors provides tangible evidence that regulatory risk has been actively mitigated. This is particularly valuable for mid-size companies where a single facility investment represents a material portion of the organization’s capital budget.

Workforce Development

PreCheck participation requires personnel with specific competencies in regulatory science, quality systems management, and pharmaceutical manufacturing technology. Organizations that invest early in building these capabilities will be better positioned not only for PreCheck but for the broader trend toward more sophisticated regulatory engagement across the industry.

Challenges and Limitations to Consider

While the benefits of PreCheck participation are meaningful, organizations should approach the program with realistic expectations about its limitations and the challenges involved in participation.

Pilot phase uncertainty: As a pilot program, PreCheck’s procedures, criteria, and outcomes may evolve as the FDA gains experience. Early participants accept a degree of procedural uncertainty that later participants will not face. The agency has been transparent about this, but organizations with low tolerance for ambiguity may prefer to wait for the program to stabilize.

Resource requirements: Preparing for and participating in PreCheck requires significant organizational resources. The facility information package is a substantial undertaking, and the collaborative assessment process demands sustained engagement from senior quality and manufacturing personnel. Organizations must weigh these resource demands against other operational priorities.

No guarantee of product-specific approval: A favorable PreCheck determination is not a product approval and does not guarantee that any specific product manufactured at the facility will be approved. Product-specific chemistry, manufacturing, and controls (CMC) review remains a separate process. PreCheck reduces facility-related risk but does not eliminate product development risk.

Ongoing compliance obligations: A PreCheck determination is not permanent. Facilities must maintain cGMP compliance continuously, and the FDA retains authority to conduct routine surveillance inspections at any time. A facility that achieves PreCheck status but subsequently allows its quality systems to deteriorate will lose whatever advantage the determination provided.

Limited scope during pilot: The number of facilities that can participate during the pilot phase is inherently limited by FDA resource constraints. Organizations interested in participation should express interest early but should also plan for the possibility that acceptance may be delayed or that the program’s capacity may not match demand.

Preparing Your Organization for PreCheck

For organizations seriously considering PreCheck participation, preparation should begin well before submitting an expression of interest. The following areas warrant early attention and investment.

Conduct a PreCheck Readiness Assessment

Before engaging with the FDA, conduct an internal assessment of your facility’s readiness against the expected PreCheck criteria. This assessment should cover physical plant condition, quality system maturity, digital infrastructure adequacy, data integrity compliance, personnel competency, and documentation completeness. Engage experienced quality consultants or former FDA reviewers to provide objective perspectives on readiness gaps.

Invest in Digital Infrastructure Early

The digital systems that PreCheck participation requires, including eQMS platforms, MES implementations, environmental monitoring integrations, and data integrity frameworks, require significant lead time to implement and validate. Organizations that wait until they are preparing the facility information package to begin these implementations will face compressed timelines and elevated project risk.

Build Regulatory Intelligence Capability

Monitor the FDA’s PreCheck-related communications, guidance documents, and public meetings closely. The program is evolving, and organizations that stay current on developments will be better positioned to adapt their preparation activities. Designate a team member or working group to track PreCheck developments and disseminate relevant information across the organization.

Develop Cross-Functional Alignment

PreCheck participation involves quality, manufacturing, regulatory affairs, IT, facilities, and finance functions. Establishing a cross-functional steering committee early in the preparation process ensures that all relevant perspectives are incorporated and that resource allocation decisions are made with full organizational awareness of the program’s requirements and benefits.

Create a Comprehensive Documentation Strategy

The facility information package is the most document-intensive element of PreCheck participation. Developing a documentation strategy that identifies required documents, assigns ownership, establishes review and approval workflows, and sets completion milestones will prevent last-minute scrambling and improve the quality of the submission. Consider engaging technical writers with pharmaceutical regulatory experience to support the effort.

The FDA PreCheck pilot program represents an important evolution in how the agency supports domestic pharmaceutical manufacturing. For organizations willing to invest in the preparation required, the program offers a pathway to reduced regulatory uncertainty, accelerated timelines, and stronger competitive positioning. The investment in quality systems, digital infrastructure, and organizational readiness required for PreCheck participation also delivers lasting value independent of the program itself, building the kind of manufacturing excellence that defines leading pharmaceutical operations.

At Sakara Digital, we help pharmaceutical and life sciences organizations evaluate digital readiness for emerging regulatory programs, design quality system architectures that support advanced manufacturing oversight, and build the technology foundations that PreCheck and similar initiatives demand. If your organization is considering domestic manufacturing expansion, contact our team for a confidential assessment of your digital and quality infrastructure readiness.